Bavarian Nordic Gestion

Gestion contrôle des critères 4/4

Le PDG Bavarian Nordic est Paul Chaplin, nommé en Jun2014, a un mandat de 10.42 ans. La rémunération annuelle totale est DKK 23.43M, composée du salaire de 30.7% et des bonus 69.3%, y compris les actions et options de la société. détient directement 0.11% des actions de la société, d'une valeur de $ 2.21M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 3.8 ans.

Informations clés

Paul Chaplin

Directeur général

DKK 23.4m

Rémunération totale

Pourcentage du salaire du PDG	30.7%
Durée du mandat du directeur général	10.4yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Paul Chaplin a-t-elle évolué par rapport aux bénéfices de Bavarian Nordic?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	DKK 1b
Jun 30 2024	n/a	n/a	DKK 707m
Mar 31 2024	n/a	n/a	DKK 984m
Dec 31 2023	DKK 23m	DKK 7m	DKK 1b
Sep 30 2023	n/a	n/a	DKK 723m
Jun 30 2023	n/a	n/a	DKK 1b
Mar 31 2023	n/a	n/a	DKK 301m
Dec 31 2022	DKK 22m	DKK 6m	-DKK 347m
Sep 30 2022	n/a	n/a	-DKK 599m
Jun 30 2022	n/a	n/a	-DKK 693m
Mar 31 2022	n/a	n/a	-DKK 606m
Dec 31 2021	DKK 18m	DKK 6m	-DKK 465m
Sep 30 2021	n/a	n/a	-DKK 737m
Jun 30 2021	n/a	n/a	-DKK 629m
Mar 31 2021	n/a	n/a	-DKK 368m
Dec 31 2020	DKK 14m	DKK 5m	DKK 278m
Sep 30 2020	n/a	n/a	DKK 606m
Jun 30 2020	n/a	n/a	DKK 481m
Mar 31 2020	n/a	n/a	DKK 267m
Dec 31 2019	DKK 12m	DKK 5m	-DKK 347m
Sep 30 2019	n/a	n/a	-DKK 402m
Jun 30 2019	n/a	n/a	-DKK 271m
Mar 31 2019	n/a	n/a	-DKK 279m
Dec 31 2018	DKK 12m	DKK 6m	-DKK 362m
Sep 30 2018	n/a	n/a	-DKK 445m
Jun 30 2018	n/a	n/a	-DKK 151m
Mar 31 2018	n/a	n/a	DKK 5m
Dec 31 2017	DKK 13m	DKK 5m	DKK 181m

Rémunération vs marché: La rémunération totale de Paul ($USD 3.31M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.34M ).

Rémunération et revenus: La rémunération de Paul a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Paul Chaplin (57 yo)

10.4yrs

Titularisation

DKK 23,428,000

Compensation

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Paul Chaplin	CEO & President	10.4yrs	DKK 23.43m	0.11% $ 2.2m
Henrik Juuel	CFO & Executive VP	6yrs	DKK 12.23m	pas de données
Russell Thirsk	Executive VP & COO	2.6yrs	pas de données	pas de données
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	pas de données	pas de données
Anu Kerns	Executive VP and Chief People & Sustainability Officer	4yrs	pas de données	pas de données
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.8yrs	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de BVNR.Y est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Peter Kürstein-Jensen	Independent Director	12.6yrs	DKK 740.00k	0.026% $ 537.7k
Anders Pedersen	Deputy Chairman	14.6yrs	DKK 1.13m	0.024% $ 496.1k
Franciscus A. G. Verwiel	Independent Director	8.6yrs	DKK 830.00k	0.0055% $ 112.8k
Anne Eberhard	Independent Director	5.6yrs	DKK 860.00k	0.0034% $ 70.9k
Luc Debruyne	Independent Chairman	1.7yrs	DKK 1.43m	pas de données
Heidi Hunter	Independent Director	1.8yrs	DKK 635.00k	pas de données
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% $ 14.4k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.0024% $ 48.7k
Anja Gjol	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% $ 14.4k
Karen Merete Jensen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00062% $ 12.7k
Johan Hoof	Independent Director	1.8yrs	DKK 575.00k	pas de données
Montse Picart	Independent Director	less than a year	pas de données	pas de données

3.8yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BVNR.Y sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Bavarian Nordic Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

Bavarian Nordic A/S Secures Second Part of Smallpox Vaccine Order from the U.S. Government

Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses

Bavarian Nordic A/S to Report Q2, 2021 Results on Aug 25, 2021

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Bavarian Nordic A/S to Report Fiscal Year 2020 Results on Mar 12, 2021

Analyse de la rémunération des PDG

PDG

Titularisation